Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06101069 · ClinicalTrials.gov registry record · NA
Development of MRF for Characterization of Brain Tumors After Radiotherapy
A NA study of Glioma and Brain Tumor, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT06101069 is a NA study of Glioma and Brain Tumor that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 60 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06101069, a NA study of Glioma and Brain Tumor, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participants will consist of individuals who have received radiation therapy in the past and were diagnosed with radiation necrosis, individuals with recurrent tumors, individuals with previously untreated tumors, and healthy individuals who have no brain diseases and have not had radiation treatment to the brain. Participants will undergo an MRI scan at a one-time research study visit; no extra tests or procedures will be required for this research study. The primary objectives of this study are: * To demonstrate the clinical feasibility of combining MRF with state-of-the-art parallel imaging techniques to achieve high-resolution quantitative imaging within a reasonable scan time of 5 min for whole brain coverage. * To apply the developed quantitative approach in combination with IVIM MRI for differentiation of tumor recurrence and radiation necrosis. * To investigate the effect of radiation dose on the development of radiation necrosis and tumor recurrence.
Conditions Studied
Interventions
- PROCEDURE MRF in conjunction with IVIM MRI without contrast
Study Locations (2)
Ohio
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center - Cleveland
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06101069
The ClinicalTrials.gov registry entry for NCT06101069 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (71% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which MRF in conjunction with IVIM MRI without contrast is the first listed.
NCT06101069 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06101069 about?
NCT06101069 is a clinical study titled "Development of MRF for Characterization of Brain Tumors After Radiotherapy". The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quan...
What is the current status of trial NCT06101069?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-10-14. Estimated completion is 2026-09.
What conditions does trial NCT06101069 study?
This clinical trial studies the following conditions: Glioma, Brain Tumor, Brain Metastases, Brain Necrosis.
What interventions are being tested in trial NCT06101069?
The interventions under investigation include: MRF in conjunction with IVIM MRI without contrast (PROCEDURE).
Who is sponsoring clinical trial NCT06101069?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06101069 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
ASCENT Intervention for Brain Tumor Patients
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.